The ClinGen Inborn Errors of Metabolism Working Group was tasked with creating a comprehensive, standardized knowledge base of genes and variants for metabolic diseases. Phenylalanine hydroxylase (PAH) deficiency was chosen to pilot development of the Working Group's standards and guidelines. A PAH variant curation expert panel (VCEP) was created to facilitate this process.
INTRODUCTION
The goals of ClinGen relevant for the IEM CDWG include sharing genomic and phenotypic data for clinical and research use, standardization of annotation and interpretation of genomic variants, use of evidence-based expert consensus for gene and variant curation, and assessing the medical actionability of genes and variants . Following these goals, the IEM CDWG chose phenylalanine hydroxylase (PAH) deficiency as a pilot for standardization of variant interpretation and curation. PAH deficiency has a prominent historical role as one of the first IEM to be recognized and understood, is universally included in newborn screening, and has well-recognized diagnostic criteria. PAH is the only gene known to cause PAH deficiency, although defects in tetrahydrobiopterin (BH 4 ) metabolism (discussed below) and the cochaperone DNAJC12 are known to cause hyperphenylalaninemia (HPA) as well.
PAH deficiency is an autosomal recessive IEM caused by biallelic mutations in PAH leading to deficient PAH enzyme. PAH deficiency, commonly referred to as PKU in the classic form, is one of the more common serious genetic conditions, with an incidence of one in 13,500-19,000 births in the United States (NIH Consensus Development Panel, 2001; Scriver, 2001) . PAH converts the amino acid phenylalanine to tyrosine in the liver. In PAH deficiency, phenylalanine accumulates in blood and the central nervous system, leading to severe or profound intellectual disability if untreated. However, Bickel's discovery (Bickel, Gerrard, & Hickmans, 1953 ) that a phenylalaninerestricted diet prevented intellectual disability, and Guthrie's development of newborn screening for PKU (Guthrie & Susi, 1963 ) have led to the successful treatment of thousands of individuals. PAH deficiency is typically diagnosed by measurement of elevated blood phenylalanine levels in the absence of other causes (disorders of BH 4 metabolism, DNAJC12 deficiency, or liver disease). PAH deficiency is often classified (from most to least severe) as classic PKU, moderate PKU, mild PKU, or mild HPA depending on the maximum blood phenylalanine levels in untreated individuals (Camp et al., 2014) . BH 4 defects collectively account for approximately 2% of individuals with HPA in most populations implying that the vast majority of individuals with persistent HPA have PKU (Regier and Greene, 2017) . Disorders of BH 4 metabolism causing HPA are genetic disorders caused by deficiencies of enzymes involved in BH 4 synthesis or regeneration. These defects differ from PAH deficiency in that treatment with a phenylalaninerestricted diet is not sufficient to prevent intellectual disability and central nervous system dysfunction. The genes encoding enzymes involved in BH 4 metabolism are distinct from PAH, and this must be taken into account during development of curation guidelines for PAH.
Two pathogenic or likely pathogenic variants in PAH are found in 97%-99% of affected patients (Regier and Greene, 2017 and personal communication, McKenna Kyriss, PhD, PreventionGenetics) . However, the allelic heterogeneity in PAH makes it difficult to definitively classify variant pathogenicity. Over 1,000 variants have been described in PAH, corresponding with 2,589 different genotypes (www.BIOPKU.org, the Phenylalanine Hydroxylase Knowledgebase). More than half of the genotypes (53%) are reported in a single patient. In addition to the use of genetic testing for diagnostic confirmation, testing is also useful in classifying the severity of PAH deficiency (Okano et al., 1991) , predicting therapeutic response, excluding BH 4 disorders as the cause of HPA, and for genetic counseling. Here, we describe the process undertaken to create an infrastructure for the development of rules to assess the pathogenicity of PAH variants and the application of the rules for PAH variant curation as a model for other inborn errors of metabolism. 
METHODS

ClinGen IEM CDWG and the PAH variant curation expert panel
Adaptation and specification of ACMG-AMP variant interpretation criteria for PAH
Following ACMG-AMP standards and guidelines for the interpretation of sequence variants (Richards et al., 2015) , each criterion was reviewed by the PAH VCEP and made specific for PAH deficiency. Criteria justifications include PAH-specific adjustments of existing ACMG-AMP criteria for additional evidence, and criteria not applicable to PAH.
Any remaining criteria not specific to PAH were used as recommended.
Additionally, recommendations for using ACMG-AMP criteria from the ClinGen Sequence Variant Interpretation (SVI) working group were incorporated (Biesecker, 2018 ; https://www.clinicalgenome.org/ working-groups/sequence-variant-interpretation/). The final PAHspecific guidelines were approved by the SVI workgroup.
Assessment of existing PAH variants in ClinVar
The current state of variant annotation of PAH in ClinVar as of March 2018 was compiled from ClinVar Miner, a tool that enables detailed exploration of ClinVar submissions and provides tools for resolution of conflicting interpretation (Henrie et al., 2018) .
Selection of PAH variants for validation of interpretation guidelines
Eighty-five pilot variants were selected to validate the PAH-specific variant interpretation guidelines (Supp. Table S1 ). We included PAH variants with multiple submissions in ClinVar (7 benign/likely benign, one uncertain significance, 53 pathogenic/likely pathogenic, three conflicting interpretations), variants to assess our allele frequency cutoffs, and additional uncertain significance (US) and benign (B)/likely benign (LB) variants. These variants cover various types of alterations: missense, nonsense, splicing, synonymous, frameshift, inframe indel, initiation codon, and intronic ( Figure 1 ).
Variant review and classification
PAH variant curation began using 895 PAH missense variants listed in the professional version of Human Gene Mutation Database (HGMD).
In the pilot phase of curation and variant review, PAH VCEP member- 
Development of biocurator tools and standards
A curation Standard Operating Procedure was created for standardization and training. Our variant assessment framework was adapted from Duzkale et al. (2013) . This describes five main steps of curation:
(1) transcription of PAH databases (BioPKU and PAHdb); (2) assessment of allele frequency; (3) predicted effect on protein structure or splicing; (4) clinical significance and references from HGMD and ClinVar (for curator reference); and (5) search of primary literature. Publicly available data sources are listed in Supp. Table S2. A password-protected online open-source relational database management system was created in 2015 and stores PAH variant curation data. Specifically, a MySQL database, managed and accessed by PHPMyAdmin was created as an online curation workspace that allows for live editing and data input. This enabled self-assignment of variants for curation to avoid duplicated efforts while optimizing curator workload, and allowed for detailed tracking of the curation effort. Data can be exported and archived.
ClinGen Variant Curation Interface
The ClinGen 
RESULTS
Existing ACMG-AMP SVI rules were adjusted for PAH based on disease (6) or strength (5) or both (2) ( Table 1) . Disease adjustments include allele frequency thresholds, functional assay thresholds, and phenotype-specific guidelines.
ACMG-AMP criteria specification for PAH
PS2: De novo occurrence (paternity confirmed)
In PAH deficiency, as with other autosomal recessive disorders, de novo variants are extremely rare. However, when it occurs, PS2 is only applicable when the case also has another known pathogenic variant in trans with the de novo variant.
PS3: In vitro functional studies
The PAH VCEP reviewed all described functional assays and recommended a well-established in vitro PAH enzyme activity assay used by multiple investigators (Gjetting, Petersen, Guldberg, & Güttler, 2001; Kim et al., 2006; Okano et al., 1991; Pey, Desviat, Gámez, Ugarte, & Pérez, 2003; Trunzo et al., 2016; Waters, Parniak, Nowacki, & Scriver, 1998 ) that expresses the variant allele in cultured cells, and measures the enzyme activity in comparison to the wild-type enzyme activity.
Residual mutant enzyme activity of 0%-50% can be used as PS3 evidence. If there are no reports of a variant having a deleterious impact using other assays (e.g., reaction kinetics, protein aggregation and folding), use of BS3_supporting could be applied for variants with mutant in vitro enzyme activities similar to wild type. 
PM3: Detected in trans with a pathogenic variant
Allele frequency (BA1, BS1, and PM2)
In PAH deficiency, allele frequency was set for BA1 at 1.5% or 0.015 using an allele frequency calculator (https://www.cardiodb.org/ allelefrequencyapp/). This calculator uses disease prevalence, genetic heterogeneity of 90% (to account for defects of BH 4 metabolism), and penetrance of 80% (to account for individuals who come to attention after becoming clinically symptomatic). The allele frequencies of the most common PAH pathogenic variants from ExAC (Lek et al., 2016) and gnomAD were used to assess the BS1 (Allele frequency greater than expected for disease) threshold. The most frequent PAH pathogenic variant, c.1222C>T (p.Arg408Trp), has a minor allele frequency of 0.1728% in gnomAD, so 0.002 or 0.2% was used for BS1. The PM2 threshold was then set at an order of magnitude lower, allele frequency of 0.0002 or 0.02%, as recommended by the SVI working group.
We then assessed other PAH variants with frequencies in these ranges ( Figure 2 ). Although six additional known pathogenic variants have allele frequencies between 0.0002 and 0.002, they remained pathogenic even if PM2 was not applied (Supp . Table S1 ). Similarly, known benign PAH variants all had allele frequencies over 0.002, and were closer to 0.015 and above.
PP4: Patient phenotype
The supporting pathogenic evidence, PP4, was applied to PAH to reflect the clinical diagnostic criteria for PAH deficiency: phenylalanine concentration persistently above 120 mol/L (2 mg/dl) (Vockley et al., 2014) . If either normal urine pterins and normal dihydropterin reductase (DHPR) activity or DNA sequencing of genes in the BH 4 cofactor metabolism pathway is performed, this evidence is upgraded to PP4_Moderate.
Existing PAH variants in ClinVar
There are a total of 655 PAH variants in ClinVar (Figure 3) 
Validation of the PAH-specific ACMG-AMP variant interpretation guidelines
Using the PAH-specific variant interpretation guidelines, 67 validation variants were classified by the PAH VCEP as pathogenic (50) Table S1 ). Eleven of the variants have clinically discordant interpretations between PAH VCEP and ClinVar submitters (Table 3) . For the three variants with conflicting interpretations (P/LP vs. VUS) in ClinVar, we classified them as likely pathogenic using the PAH-specific guidelines (Table 2 ). 
PAH variant curation by the PAH VCEP
DISCUSSION
Lumping versus splitting
When deciding how to curate variants in the PAH gene, the question arose whether to associate the variant with a specific phenotype (e.g., mild HPA or classic PKU), which can be referred to as "splitting" the gene-disease association. There is an abundance of literature that has attempted to categorize the PAH genotype-phenotype correlation, while acknowledging that two alleles contribute to the phenotype (Guldberg et al., 1998; Guttler, 1994; Kayaalp et al., 1997; Okano et al., 1991) . Splitting gene-disease phenotypes may be more applicable for genes with distinct syndromes and differing molecular mechanisms (https://www.clinicalgenome.org/working-groups/lumping-and-splitti ng/). The PAH VCEP decided to "lump" together the described PAH deficiency phenotypes (classic PKU, moderate PKU, mild PKU, and mild HPA), and not to associate PAH variants with a specific phenotypic 
Using a biochemical phenotype
A challenge of applying existing ACMG-AMP criteria was to adequately represent current clinical diagnostic methods for PAH deficiency using the variant interpretation evidence categories. Many IEM are detected by newborn screening before symptoms, or a typical phenotype, develop. Instead of using a clinical phenotype of untreated PAH deficiency (e.g., intellectual disability) as evidence for PP4 criteria, we chose to use a biochemical phenotype of elevated plasma phenylalanine levels to be consistent with current ACMGG diagnostic criteria for PAH deficiency (Vockley et al., 2014 
Applying functional assays
An established assessment of PAH variant pathogenicity are in vitro enzyme assays (Gjetting et al., 2001; Kim et al., 2006; Okano et al., 1991; Pey et al., 2003; Trunzo et al., 2016; Waters et al., 1998) . They directly reflect the specific variant, and are not subject to confounding effects of the other allele. These satisfy the functional assay criteria (PS3), but certain aspects of these assays were evaluated. One concern was that these assays are research studies and are not performed in a regulated environment (e.g., CLIA lab test or using a commercially available kit). So consideration was given to mutant enzyme activity studies in triplicate. Shen et al., 2016; Trunzo, 2016) . Also, a cut-off had to be determined for standardization as to what constituted a deleterious effect on the enzyme. Gjetting et al. (2001) 
Allele frequency thresholds
Typically, the PAH variants reported in affected individuals are absent from the population databases, or at an extremely low frequency. However, a cutoff for allele frequency was necessary in order to standardize curation. ACMG-AMP guidelines state that allele frequency for pathogenic variants in recessive disease should be consistent with disease incidence/carrier frequency (Richards et al., 2015) , suggesting an allele frequency for a PAH variant of 2.0% meets criteria for BS1. However, this was adjusted to 0.2%-1.5% using an allele frequency calculator and frequent PAH variants with known pathogenicity. This lower threshold reflects the genetic heterogeneity of PAH variants, and the lack of a frequent pathogenic variant that approaches the carrier frequency. When approaching the modification of ACMG-AMP criteria for recessive disease, allele frequency thresholds could be assessed using known pathogenic and benign variants, and a calculator that takes into account disease specific aspects. 
Expanding the number of PAH variants with clinical interpretation
Limitations
One of the challenges was to modify the ACMG-AMP criteria for variant interpretation for PAH, for which a well-defined biochemical phenotype exists. The pathogenicity of a variant can be assigned based on the effect on the protein. Hence, the effect on protein activity is estimated from the concentration of phenylalanine in plasma/serum/blood spots. This depends not only on enzymatic activity but also on phenylalanine intake which cannot always be measured accurately due to variable dietary compliance and reporting. In addition, for several PAH variants the lack of evidence in the literature that other causes of elevated phenylalanine had been excluded limits our ability to properly assess their pathogenic criteria. Finally, we are just now entering the era of genome sequencing and the presence of additional variants in the regulatory regions of the gene in cis with the observed exonic variant cannot be excluded.
CONCLUSIONS AND FUTURE DIRECTIONS
The ClinGen IEM CDWG was tasked with creating a comprehensive, standardized knowledge base of genes and variants for metabolic diseases. PAH deficiency was chosen to pilot development of the Working Group's standards and guidelines. The specifications of the guidelines outlined above and application of these guidelines to classify over 1,000 variants at the PAH locus has led to a near complete characterization of pathogenicity for what is one of the most mutated genes in humans. This exemplar creates a pathway forward in curating the hundreds of distinct inborn errors of metabolism, providing guidance in weighing the impact on pathogenicity scoring of disease-specific analytes, and incorporating additional biochemical phenotypes and in vitro enzyme assays. While each IEM has its own unique features, our experience will help inform future efforts with these other autosomal recessive conditions. With completion of the PAH pilot the IEM CDWG has created sub-groups that are tackling pathway-specific domains (e.g., fatty acid oxidation disorders, aminoacidopathies, and lysosomal storage disorders), assembling teams with domain-specific clinical expertise and biocuration capacity, followed by completing the required gene curation before addressing variant curation. A broad expansion of these sub-groups will be required to complete these tasks in an achievable time frame. 
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